Compare IDN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | CING |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 64.5M |
| IPO Year | 2014 | 2021 |
| Metric | IDN | CING |
|---|---|---|
| Price | $2.82 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.33 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 463.7K | 146.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 56.47 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $47.33 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.70 | $3.16 |
| 52 Week High | $9.08 | $11.89 |
| Indicator | IDN | CING |
|---|---|---|
| Relative Strength Index (RSI) | 27.47 | 55.62 |
| Support Level | $2.70 | $4.76 |
| Resistance Level | $4.49 | $5.54 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 11.40 | 56.06 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.